Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Gilead, Merck step in to help India's drug manufacturers fight surging COVID-19 outbreak
UHS posts $209M profit in Q1 after treating high number of COVID-19 patients
Insights into how COVID outsmarts the gut's immune response could point to new treatments
COVID-19 tracker: J&J shot could prevent 1,400 deaths in 6 months, CDC says; Pfizer's oral drug could come by year end
Jubilant wraps up early clinical tests of oral remdesivir, plots further studies
UPDATED Coronavirus tracker: CDC eases outdoor mask guidelines for fully vaccinated people
Kry raises $316M to scale its telehealth platform across Europe
Centene has added 320K members on ACA exchanges under special enrollment period

Featured Story

Gilead, Merck step in to help India's drug manufacturers fight surging COVID-19 outbreak

By Noah Higgins-Dunn

Gilead Sciences and Merck have unveiled plans to boost production for their antiviral COVID-19 drugs in India to help the nation battle its worsening outbreak.

UHS posts $209M profit in Q1 after treating high number of COVID-19 patients

By Robert King

Universal Health Services posted a $209 million profit for the first quarter of 2021 as a double-digit increase in patient service revenue offset lingering declines in volumes.

Insights into how COVID outsmarts the gut's immune response could point to new treatments

By Arlene Weintraub

European researchers used 3D tissue models, or organoids, of the human gut to determine that a particular subpopulation of cells is most affected by SARS-CoV-2. The enhanced understanding of those cells mount an immune response to the virus could enhance the search for new COVID-19 therapies, they said.

COVID-19 tracker: J&J shot could prevent 1,400 deaths in 6 months, CDC says; Pfizer's oral drug could come by year end

By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky

Johnson & Johnson's COVID-19 vaccine could save up to 1,400 lives in the next six months if the U.S. continues to administer the vaccine, a new CDC reports shows. Pfizer chief Albert Bourla tells CNBC that the company's oral antiviral could be available by the end of the year. And more headlines.

Jubilant wraps up early clinical tests of oral remdesivir, plots further studies

By Nick Paul Taylor

Jubilant Pharma has completed initial tests of its oral remdesivir formulation in healthy volunteers. The progress led Jubilant to seek authorization to run additional studies of its oral twist on Gilead’s intravenous COVID-19 antiviral.

UPDATED Coronavirus tracker: CDC eases outdoor mask guidelines for fully vaccinated people

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Kry raises $316M to scale its telehealth platform across Europe

By Andrea Park

With more than $300 million in additional backing, Kry will pursue a strategy of rapid expansion. The startup plans to recruit new members to its team, look into potential acquisitions and partnerships and grow its platform in nearly every direction.

Centene has added 320K members on ACA exchanges under special enrollment period

By Paige Minemyer

Centene Corporation posted $699 million in profit for the first quarter of 2021, up from $46 million in the prior-year quarter.

COVID-19 Tracker